If you caught the premarket buzz this morning, you saw Catheter Precision making a huge splash with its stock soaring about 114% to roughly $0.4892. So, what’s behind this surge for the small-cap medtech company?
First, the big news is VTAK’s first purchase order for its VIVO product from Sahlgrenska University Hospital in Sweden – a major player treating 350,000 patients annually and running the region’s largest ventricular ablation program. This deal signals strong clinical validation and potential for future sales, especially as CEO David Jenkins plans to train more physicians on their tech.
Next, VTAK’s LockeT product just got CE Mark approval, opening doors to sell across the EU, UK, Switzerland, and Turkey. The European market for this kind of tech is booming, valued at $3.1 billion in 2024 and expected to grow to $4.3 billion by 2028. They’ve already secured an order for 100 units and are in talks with distributors to expand further.
That said, VTAK is still a small-cap stock with risks. They have $24.8 million in total assets, $7.9 million in shareholders’ equity, but only $450,000 in cash as of March 31, 2025. The company is burning cash and will need to maintain momentum to sustain growth.
